Cytomegalovirus (CMV) is the most common congenital infection in humans and a leading cause of sensorineural hearing loss. Ganciclovir (6 mg/kg twice daily for 42 days) has been shown to reduce hearing deterioration and is used in clinical practice. Vaccines and passive administration of antibody are being evaluated in randomized controlled trials in allograft candidates, women of childbearing age, and pregnant women with primary CMV infection. To help define genetic variation in each of the targets of these therapeutic interventions, we amplified and sequenced genes UL97 (site utilised for ganciclovir phosphorylation), UL55 (glycoprotein B (gB) vaccine target) and UL128, UL130, and UL131a (specific monoclonal antibody targets). Serial blood, saliva, and urine samples (total 120) obtained from nine infants with symptomatic congenital CMV treated with 42 days' ganciclovir were analyzed. All samples tested were UL97 wild type at baseline and none developed mutations during treatment, showing no selection of resistance. The prevalences of UL55 genotypes were 28% gB1, 22% gB2, 1% gB3, and mixed in 20% samples. No mutations were noted in UL128-131a. Phylogenetic tree analysis showed that sequences with variations were found in multiple body sites of individual patients, so there was no evidence of body site compartmentalization of particular strains of CMV. The significance of these results for changes in diagnostic practices and therapeutic interventions against CMV are discussed.
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INTRODUCTION
Congenital CMV infection is estimated to affect 0.7 per 1,000 live births worldwide [Dollard et al., 2007] . Around 25% of babies born with congenital CMV develop some form of permanent neurological impairment, primarily sensorineuronal hearing loss (SNHL), and intellectual and developmental disabilities, with approximately one third having symptoms at birth [Dollard et al., 2007] . Congenital CMV can be due to maternal primary infection in pregnancy, reinfection with a new strain, or reactivation from latency [Gaytant et al., 2002; De Vries et al., 2013] .
A phase III randomized controlled trial (RCT) demonstrated that 6 weeks (6 mg/kg twice daily) of intravenous ganciclovir therapy started in the 1st month of life reduced hearing deterioration and improved neurological outcomes in newborns with congenital CMV, and evidence of central nervous system (CNS) disease [Kimberlin et al., 2003; Oliver et al., 2009] . The protein kinase encoded by CMV gene UL97 phosphorylates ganciclovir to its active form and UL97 mutations impair ganciclovir phosphorylation with 90% of resistance mutations to ganciclovir occurring in the UL97 gene between amino acids 460-520 [Chou, 2008] . Resistance is suspected clinically after solid organ transplant when viral load increases despite treatment and can be confirmed by sequencing the UL97 gene [Chou, 2008] . Theoretical and clinical studies in solid organ transplant recipients show that therapy lasting for longer than 100 days is needed to select for resistance to ganciclovir [Emery and Griffiths, 2000; Limaye et al., 2000; Limaye, 2002; Lurain et al., 2002] . No published studies have assessed whether short courses of treatment in neonates selects for ganciclovir-resistant strains of CMV.
In clinical studies of neonates, viral load is usually suppressed during 6 weeks of treatment but rebounds in blood, urine, and saliva samples [Whitley et al., 1997; Luck and Atkinson, 2009 ]. This pattern is consistent with viral replication recovering once the antiviral drug pressure is stopped, rather than selection of resistance, but it is important to document this, especially now that longer courses of treatment with ganciclovir are being evaluated in a RCT (NCT00466817).
This cohort of symptomatic babies was used to assess genetic variation in additional genes that are currently targets for therapeutic intervention against CMV. Two phase II vaccine trials have been conducted in the last 6 years with promising results of recombinant soluble glycoprotein B (gB) vaccine in women of childbearing age and in solid organ transplant candidates Griffiths et al., 2011] . Five distinct genotypes (gB 1-5) have been identified in infants with congenital CMV and co-infection with multiple strains reported .
This study also examined variation in genes that are the target of a current RCT attempting to interrupt transmission of CMV from donor to recipient during renal transplantation (NCT01753167) and a third target for therapeutic intervention. Proteins encoded by the UL128-131a gene loci form a pentameric complex with the antigens glycoprotein L and glycoprotein H [Macagno et al., 2010] . The UL128-131a region is a major determinant of virus entry into epithelial cells [Macagno et al., 2010] . Monoclonal antibodies against these proteins that have high neutralizing activity against CMV are infused at the time of transplant and the proportion of infected recipients compared to that found in recipients of placebo. As with the gB vaccine mentioned above, parallel studies of this monoclonal antibody preparation in women of childbearing age could be envisaged with the objective of reducing maternal-fetal transfer of CMV. Hyperimmune immunoglobulin has recently been evaluated during pregnancy for this purpose but did not significantly alter the course of infection during pregnancy [Revello et al., 2014] .
The final aim of this study was to address a change in contemporary diagnosis of congenital CMV infection. Although urine is still most commonly used for diagnosing suspected clinical infection at birth, the detection of CMV using PCR of dried blood spots, and saliva are gaining a role in both the retrospective diagnosis of CMV and in screening programmes [Walter et al., 2008; Boppana et al., 2010 Boppana et al., , 2011 . Previous studies show that multiple genotypes are present in samples taken within the 1st weeks of life with distinct strains found in different body compartments as shown by genotyping of gB, gH, and gN . None of the infants were reported to be symptomatic or to receive treatment for congenital CMV .
Given the above observations, this study aimed to evaluate variation in CMV genes with possible relevance to pathogenesis or treatment. This study examined different body compartments of treated infants and determined whether genetic changes segregated by patient or by body site.
MATERIALS AND METHODS

Patient Samples
Blood, saliva, and urine samples were analyzed from nine infants with congenital CMV recruited from four different paediatric units in the ethically approved Viral Load and Immunity in Congenital CMV (VICC) study during 2008-2010. Eight infants had been treated with 42 days ganciclovir treatment and one infant with 42 days ganciclovir followed by 39 days of valganciclovir. Samples were obtained at days 7, 28, 42 of treatment, 7 days post-treatment and 3, 6, and 9 months of life.
Samples with CMV viral loads >2.5 log 10 were selected for analysis to increase the likelihood of there being sufficient genetic material for analysis.
DNA Extraction of CMV DNA Using the Biomerieux Automated Extractor
Total nucleic acid was extracted using the commercial Nuclisense Easymag system (Biomerieux, Basingstoke UK). This is a semi-automated system based on a nucleic acid purification method developed by Boom et al. [1990] with enhanced magnetic silica technology. DNA was extracted according to the manufacturer's instructions.
UL97 Population Sequencing
The UL97 region (codons 550-645) was characterized using a method published previously by Castor et al. [2007] with the following modifications to the cycling programme. The PCR programme was: denaturation at 94˚C for 2 min, followed by 45 cycles of 94˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 1 min. Final elongation was carried out at 78˚C for 4 min, with cooling at 37˚C for 1 min. PCR product was visualized on agarose gel prior to cycle sequencing. 
Genotyping of Cytomegalovirus
PCR Amplification of UL128-131a
Primer sequences to cover known sequence polymorphisms within the UL128-131a regions were modified from a method published previously [Vogel et al., 2013] .
DNA Sequencing and Phylogenetic Analysis
Sequencing was performed using the ABI Prism BigDye terminator cycle sequencing kit (v3.1), on an Applied Biosystems 3730 DNA analyzer. Sequences were analyzed using Applied Biosystems SeqScape software with Genbank accession numbers of G221975, FJ527563, GQ221974, GQ466044, and AY446894 used as CMV reference sequences. Phylogenetic trees were constructed using an online phylogenetic tree maker http://www.hiv.lanl.gov/ content/sequence/PHYML/interface.html.
RESULTS
UL97
Sequencing data were obtained from 20 blood, 24 saliva, and 24 urine samples taken at four time points during and after ganciclovir treatment (days 7, 28, 42, and 7 days post-treatment). Not all patients had all samples available at each time point, but sequence data were obtained from all specimens tested. Results showed that all samples were wild type at day 7. No known resistance mutations were identified within the UL97 region in samples taken during treatment. Phylogenetic analysis demonstrated viral segregation with the patient and not compartmentalization by body site (Fig. 1) .
Glycoprotein B
A total of 32 blood, 37 urine, and 33 saliva samples were amplified. Genotypes were obtained for 71/102 samples (70%). gB1 28% (29/102) and gB2 22% (22/102) were the most prevalent strains with gB3 identified in only one sample and no genotype available in 30% (31/102); mixed genotypes were not uncommon (gB1/gB2 16% and gB2/gB3 4% (Table I) . In 7/9 newborns the gB genotype identified in !1 compartment varied at different intervals during and after treatment. No evidence of compartmentalization by body site was noted. Mixed genotypes were not associated with sample type or time point across infants.
UL128-131a
It was possible to investigate this third region using the samples collected as it is not responsible for ganciclovir phosphorylation. A total of 36 blood, 42 urine, and 42 saliva samples were amplified from newborns on day 7 of life and at 6 months. Sequence data were obtained from all specimens tested. No mutations were identified in any of the samples sequenced. Results obtained from UL128-UL131a sequencing data in blood, saliva, and urine show the virus segregating with the patient and not the body compartment.
DISCUSSION
Although the number of cases available to us was small, they have the advantage of representing a population known to benefit from therapeutic interventions; congenital CMV infection born with symptoms. Natural history studies show that 32% of pregnant women with primary CMV infection transfer virus across the placenta and that approximately 13.5% of infected babies are born with symptoms while another 12.7% develop symptoms on follow up [Dollard et al., 2007; Kenneson and Cannon, 2007] . It is possible that those who suffer from this infection represent a subset of infected individuals because one or more strains of CMV has above average pathogenicity. If this were true, it would be important to document the genetic composition of these proposed more pathogenic viruses.
Results from the cohort presented demonstrate that 42 days of treatment with ganciclovir does not frequently select for resistance mutations in the UL97 gene. The region sequenced covered codons 439-645 of the UL97 gene. This area has been shown in a previous study to include all clinically relevant ganciclovir mutations [Chou, 2008] . We cannot exclude, however, that as yet undefined mutations exist outside this region. These results suggest that the rebound in viral load seen at the end of treatment is more likely due to the natural dynamic nature of CMV replication rather than antiviral resistance [Emery and Griffiths, 2000] . It will be interesting to see whether, in contrast, the recently completed study of a longer course of 6 months' valganciclovir in neonates selects for resistant strains (NCT00466817).
Our studies of other loci give the impression of genetic stability within CMV, with no evidence that these symptomatic babies have been infected with unusual strains of virus and no significant sequence variation observed. In addition, in contrast to Ross's study of babies not reported to be symptomatic, this study found no evidence of body site compartmentalization, because genetic variants segregated with individual patients rather than by body site which could be due to ganciclovir enhancing selection of strains . This implies that changes in diagnostic practices toward preferring saliva and blood over urine should not introduce major biases into studies of CMV genetics. The epitopes within the UL130 complex that are targeted by a current study of passive infusion of monoclonal antibodies appear to be conformational, so interpretation is complex, but the polymorphisms seen do not suggest major changes from the wild-type virus.
Genetic variation was seen for gB; as in previous studies, gB 1 was the predominant genotype in these congenitally infected infants . Table  I highlights a complex relationship between genotype, body compartment, and time point. A possible explanation is a combination of transplacental transfer of more than one maternal strain (cases 3, 4, 5, and 7) and postnatal reinfection from multiple CMV strains (cases 1 and 8) in congenitally infected newborns. Re-infection with another strain may induce symptoms. However, this data were unavailable for the study. No maternal samples were available for sequencing and so it was not possible to demonstrate the presence of the same genotypes present in a mother and her infected newborn as has been shown in other studies [Yamamoto et al., 2007] . Future studies could consider prospectively collecting samples from other family members to determine if they are the source of CMV reinfections during the 1st year of life.
As regards the implications of genetic variation in gB for the potential to control CMV infection using vaccines containing gB, the variations seen mapped to antigenic domains 2 and 4 among the 5 identified by P€ otzsch et al. [2011] . Interpretation is complex, because some of the epitopes are linear, whereas, others are conformational. It is hoped that these and other reports of genetic variation in gB will aid future three-dimensional modeling of the structure of gBs, and identify any predicted effects on the ability of antibodies to bind gB variants.
This study amplified viral DNA direct from clinical specimens giving it an advantage over studies using cell cultures which can select for different virus strains [Dargan et al., 2010] . The use of population sequencing in this study, however, means that genotypes are only identifiable once they account for approximately 20% of the sequence population [Lurain and Chou 2010] . Mutations present at lower levels can be detected with pyrosequencing ($6%) and ultra-deep sequencing ( 1%) [Renzette et al., 2011] . Future studies employing these newer methods could determine if even more variation is seen and consider virus evolution over longer periods of time. 
